- Conditions
- Status Epilepticus, Seizure, Epilepsy, Refractory Status Epilepticus, Medically Resistant Status Epilepticus
- Interventions
- Ketogenic diet
- Dietary Supplement
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Honolulu, Hawaii • Chicago, Illinois + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Focal Epilepsy, Generalized Seizure, Drug Refractory Epilepsy
- Interventions
- UNEEG SubQ device
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
- Interventions
- Anakinra, Tocilizumab, Standard medical treatment
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 17 more
- Conditions
- Partial Epilepsy
- Interventions
- 800 mg QD Eslicarbazepine acetate, 1200 mg QD Eslicarbazepine acetate, Placebo
- Drug
- Lead sponsor
- Bial - Portela C S.A.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 653 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 106
- States / cities
- Mobile, Alabama • Northport, Alabama • Phoenix, Arizona + 82 more
- Conditions
- Refractory Epilepsy, Deep Brain Stimulation
- Interventions
- PS and OS stimulation order 1, PS and OS stimulation order 2, PS and OS stimulation order 3
- Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Epilepsy
- Interventions
- Muscimol
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Epilepsy
- Interventions
- perampanel
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more
- Conditions
- Epilepsy
- Interventions
- Baseline MEG Test, Receptive Language Task, Memory Task
- Diagnostic Test · Behavioral
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 8 Years to 21 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Epilepsy
- Interventions
- transcranial magnetic stimulation (TMS)
- Device
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- CDKL5 Deficiency Disorder
- Interventions
- ganaxolone, Placebo
- Drug
- Lead sponsor
- Marinus Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 14 more
- Conditions
- Epilepsy (Treatment Refractory)
- Interventions
- Seizure risk forecast, Control seizure risk forecast
- Other
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Anxiety, Medication-refractory Focal-onset Epilepsy
- Interventions
- Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA)
- Device
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Drug-resistant Epilepsy, Focal-Onset Seizures
- Interventions
- Padsevonil, Placebo
- Drug · Other
- Lead sponsor
- UCB Biopharma S.P.R.L.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 411 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 27
- States / cities
- Chandler, Arizona • Little Rock, Arkansas • La Jolla, California + 21 more
- Conditions
- Epilepsies, Partial
- Interventions
- Vagus Nerve Stimulation Therapy
- Device
- Lead sponsor
- Cyberonics, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Los Angeles, California + 19 more
- Conditions
- Refractory Status Epilepticus
- Interventions
- Perampanel
- Drug
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Refractory Infantile Spasms
- Interventions
- JBPOS0101
- Drug
- Lead sponsor
- Bio-Pharm Solutions Co., Ltd.
- Industry
- Eligibility
- 6 Months to 36 Months
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 17
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 13 more
- Conditions
- Epilepsy
- Interventions
- Atkins diet (15 grams/day carbohydrates)
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Epilepsy, Lennox Gastaut Syndrome, Lennox-Gastaut Syndrome, Intractable, Seizures, Seizures, Generalized
- Interventions
- RNS System
- Device
- Lead sponsor
- NeuroPace
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 2 more
- Conditions
- Epilepsy
- Interventions
- GW273225
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 26 more
- Conditions
- Epilepsy Intractable
- Interventions
- ABI-009
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 3 Years to 26 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Post-traumatic Epilepsy
- Interventions
- PO BRC-003 (High Cannabidiol Cannabis Extract), Placebo
- Drug
- Lead sponsor
- Dr. Paul Lyons
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Winchester, Virginia
- Conditions
- Epilepsy
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 4 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neuroblastoma
- Interventions
- LY3295668 Erbumine, Topotecan, Cyclophosphamide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 7
- States / cities
- San Francisco, California • Aurora, Colorado • Chicago, Illinois + 4 more
- Conditions
- Intractable Epilepsy, Convulsive Seizures
- Interventions
- methylprednisolone sodium succinate, Placebo
- Drug · Other
- Lead sponsor
- Louisiana State University Health Sciences Center in New Orleans
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana